title: Response to: Comparison of infliximab drug measurement across three commercially available ELISA kits.
authors.affiliation: R&D Department, Progenika Biopharma-Grifols, Derio, Spain. Electronic address: daniel.nagore@progenika.grifols.com.
authors.forename: D
authors.initials: D
authors.lastname: Nagore
authors.affiliation: Product Development and Support, Progenika Biopharma, Derio, Spain.
authors.forename: N
authors.initials: N
authors.lastname: Rapún
authors.affiliation: Product Development and Support, Progenika Biopharma, Derio, Spain.
authors.forename: I
authors.initials: I
authors.lastname: Antón
authors.affiliation: Australia National Applications, Grifols Australia Ltd, Melbourne, Vic, Australia.
authors.forename: J
authors.initials: J
authors.lastname: Harper
authors.affiliation: R&D Department, Progenika Biopharma-Grifols, Derio, Spain.
authors.forename: A
authors.initials: A
authors.lastname: Martínez
mesh_terms: D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D000069285:Infliximab; D011933:Reagent Kits, Diagnostic
chemical_list: D011933:Reagent Kits, Diagnostic; D000069285:Infliximab